Aurobindo Pharma gets first US nod for alfuzosin HCL
MUMBAI, Nov 19 (Reuters) - The U.S. Food and Drug Administration has tentatively approved Aurobindo Pharma Ltd's (ARBN.BO: Quote, Profile, Research) alfuzosin hydrochloride extended release tablets, the regulator's website showed.
The drug is used to treat a non-cancerous enlarged prostate condition. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved



India
US
UK












